☆ 4.6 Article

Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma

CANCERS (2023)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification

Carla Montironi et al.

Summary: This study characterizes the immunogenomic contexture of hepatocellular carcinoma (HCC) and defines inflamed and non-inflamed tumors. Two distinct patterns of CTNNB1 are associated with differential immune evasion and may help predict immune response in HCC.

GUT (2023)

Add to Collection

Article Oncology

Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies

Masatoshi Kudo et al.

Summary: This study analyzed the correlation between objective response and overall survival in patients with advanced hepatocellular carcinoma (HCC). The results showed that OR-mRECIST is an independent predictor of overall survival and can be used as an endpoint in early-phase trials.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Gastroenterology & Hepatology

Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity

Takayuki Tokunaga et al.

Summary: For patients with unresectable hepatocellular carcinoma, achieving a favorable outcome with first- or later-line lenvatinib therapy requires high and moderate early-phase relative dose intensity, with dose modifications to match the degree of RDI and tolerance during LEN.

HEPATOLOGY RESEARCH (2022)

Add to Collection

Article Gastroenterology & Hepatology

Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis

Takeshi Hatanaka et al.

Summary: The study investigated the association between early bevacizumab interruption and the clinical outcome of atezolizumab plus bevacizumab. The results showed that bevacizumab interruption was significantly associated with objective response rate, progression-free survival, and overall survival. Good liver function and treatment settings may help maintain the efficacy of bevacizumab treatment.

HEPATOLOGY RESEARCH (2022)

Add to Collection

Article Gastroenterology & Hepatology

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann-Lii Cheng et al.

Summary: The study demonstrated that atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients led to improved survival outcomes. After updated analysis, atezolizumab plus bevacizumab maintained its position as the first-line treatment option for advanced hepatocellular carcinoma.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Morphological, dynamic and functional characteristics of liver pseudolesions and benign lesions

Matteo Renzulli et al.

Summary: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide and a common cause of death among patients with cirrhosis. The study of cirrhotic livers is challenging for radiologists due to the distortion caused by fibrous and regenerative tissue, leading to misinterpretation of benign lesions and pseudolesions as malignancies.

RADIOLOGIA MEDICA (2022)

Add to Collection

Article Gastroenterology & Hepatology

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study

Antonio D'Alessio et al.

Summary: This study confirms the reproducible safety and efficacy of AtezoBev in routine clinical practice. Patients with impaired liver function (CP-B) showed comparable tolerability to those with normal liver function (CP-A), indicating the need for prospective evaluation in this specific population.

HEPATOLOGY (2022)

Add to Collection

Review Oncology

Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations

Anthony C. Bejjani et al.

Summary: The treatment landscape for advanced hepatocellular carcinoma has undergone significant changes in recent years, with the introduction of immunotherapy and the development of various treatment regimens. Some combination therapies have shown promising results in improving outcomes for patients. However, there are still knowledge gaps in this rapidly evolving field. It is important for clinicians to stay informed about the safety and efficacy of these evolving regimens to optimize patient outcomes.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Editorial Material Oncology

Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass

Masatoshi Kudo

LIVER CANCER (2022)

Add to Collection

Article Oncology

Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study

Shigeo Shimose et al.

Summary: This study evaluated the correlation between adverse events and overall survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Liver injuries were found to have a negative impact on survival. Fatigue, liver injury, and albumin-bilirubin grade were identified as factors for discontinuation of treatment. It is important to monitor adverse events closely during atezo/beva treatments.

CANCERS (2022)

Add to Collection

Review Oncology

Molecular pathogenesis and systemic therapies for hepatocellular carcinoma

Josep M. Llovet et al.

Summary: In this article, Llovet and colleagues review recent advances in hepatocellular carcinoma therapy and discuss the clinical workflows for selecting and monitoring patients. The article covers the molecular pathogenesis of HCC, molecular classes and determinants of heterogeneity, and effective systemic therapies including immunotherapy. The authors propose a flowchart of sequential therapies, explore mechanisms of resistance, and address the need for predictive biomarkers.

NATURE CANCER (2022)

Add to Collection

Review Oncology

Immune Checkpoint Inhibitors in the Treatment of HCC

Clelia Donisi et al.

Summary: Hepatocellular carcinoma (HCC) is typically inflammation-induced neoplasia, and immune therapies such as immune checkpoint inhibitors have shown promising results in various settings of HCC treatment. Anti-PD1 and anti-CTLA-4 antibodies have been successful in advanced HCC, leading to FDA approval in the second-line setting. The combination of locoregional therapies with immune checkpoint inhibitors is under study and may represent an effective strategy for HCC treatment.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Letter Gastroenterology & Hepatology

Limited efficacy of atezolizumab and bevacizumab for hepatocellular carcinoma previously treated with tyrosine kinase inhibitor

Tomoharu Yamada et al.

LIVER INTERNATIONAL (2021)

Add to Collection

Article Oncology

Characterization of response to atezolizumab plus bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial

Riad Salem et al.

Summary: The IMbrave150 trial demonstrated significant improvement in clinical outcomes with atezolizumab + bevacizumab compared to sorafenib in unresectable hepatocellular carcinoma patients, showing higher objective response rate and deeper response depth.

CANCER MEDICINE (2021)

Add to Collection

Article Gastroenterology & Hepatology

mRECIST for HCC: Performance and novel refinements

Josep M. Llovet et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis

Atsushi Hiraoka et al.

CANCER MEDICINE (2019)

Add to Collection

Article Gastroenterology & Hepatology

AASLD guidelines for the treatment of hepatocellular carcinoma

Julie K. Heimbach et al.

HEPATOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

Jorge A. Marrero et al.

HEPATOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo et al.

LANCET (2018)

Add to Collection

Review Gastroenterology & Hepatology

Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria)

Masatoshi Kudo et al.

DIGESTIVE DISEASES (2015)

Add to Collection

Article Oncology

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

Abby B. Siegel et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.